These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36544904)

  • 1. Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin.
    Granit A; Mishra K; Barasch D; Peretz-Yablonsky T; Eyal S; Kakhlon O
    Front Cell Dev Biol; 2022; 10():1014798. PubMed ID: 36544904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells.
    Granit Mizrahi A; Gugenheim A; Hamad H; Hamed R; Tetro N; Maimon O; Khutsurauli S; Nechushtan H; Nisman B; Duran D; Samman W; Birimberg-Schwartz L; Grunewald M; Eyal S; Peretz T
    Front Cell Dev Biol; 2023; 11():1217149. PubMed ID: 37954205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
    Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The serum acylcarnitines profile in epileptic children treated with valproic acid and the protective roles of peroxisome proliferator-activated receptor
    Ma Y; Wang M; Guo S; Li T; Liu X; Zhao L
    Front Pharmacol; 2022; 13():1048728. PubMed ID: 36425583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
    Wawruszak A; Luszczki JJ; Grabarska A; Gumbarewicz E; Dmoszynska-Graniczka M; Polberg K; Stepulak A
    PLoS One; 2015; 10(11):e0143013. PubMed ID: 26580554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolomics reveals the effect of valproic acid on MCF-7 and MDA-MB-231 cells.
    Zhou X; Li Z; Wang X; Jiang G; Shan C; Liu S
    Xenobiotica; 2020 Mar; 50(3):252-260. PubMed ID: 31092106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of valproic acid induced EMT by AKT/GSK3β/β-catenin signaling pathway in triple negative breast cancer.
    Ozman Z; Ozbek Iptec B; Sahin E; Guney Eskiler G; Deveci Ozkan A; Kaleli S
    Mol Biol Rep; 2021 Feb; 48(2):1335-1343. PubMed ID: 33515347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis.
    Al-Bahlani S; Al-Lawati H; Al-Adawi M; Al-Abri N; Al-Dhahli B; Al-Adawi K
    Apoptosis; 2017 Jun; 22(6):865-876. PubMed ID: 28386750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1.
    Chen JH; Zheng YL; Xu CQ; Gu LZ; Ding ZL; Qin L; Wang Y; Fu R; Wan YF; Hu CP
    Biol Chem; 2017 Jun; 398(7):785-792. PubMed ID: 28002023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
    Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
    J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Untargeted LC-MS/MS Metabolomics Study of HO-AAVPA and VPA on Breast Cancer Cell Lines.
    Estrada-Pérez AR; García-Vázquez JB; Mendoza-Figueroa HL; Rosales-Hernández MC; Fernández-Pomares C; Correa-Basurto J
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VPA improves ferroptosis in tubular epithelial cells after cisplatin-induced acute kidney injury.
    Li Y; Li K; Zhao W; Wang H; Xue X; Chen X; Li W; Xu P; Wang K; Liu P; Tian X; Fu R
    Front Pharmacol; 2023; 14():1147772. PubMed ID: 37153759
    [No Abstract]   [Full Text] [Related]  

  • 15. Synergistic effects of combined cisplatin and
    Abu Bakar NFAB; Yeo ZL; Hussin F; Madhavan P; Lim V; Jemon K; Prabhakaran P
    J Taibah Univ Med Sci; 2023 Dec; 18(6):1220-1236. PubMed ID: 37250812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valproic acid overcomes hypoxia-induced resistance to apoptosis.
    Cipro Š; Hřebačková J; Hraběta J; Poljaková J; Eckschlager T
    Oncol Rep; 2012 Apr; 27(4):1219-26. PubMed ID: 22159638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents
    Wang D; Jing Y; Ouyang S; Liu B; Zhu T; Niu H; Tian Y
    Oncol Lett; 2013 Nov; 6(5):1492-1498. PubMed ID: 24179547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
    Pattarawat P; Wallace S; Pfisterer B; Odoi A; Wang HR
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):141-152. PubMed ID: 31865420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of valproic acid on the expression of various acyl-CoA dehydrogenases in rats.
    Kibayashi M; Nagao M; Chiba S
    Pediatr Int; 1999 Feb; 41(1):52-60. PubMed ID: 10200137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
    Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.